Klaus Schmierer (K Schmierer)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 38

Top Venues

Neurodegenerative disease management

Multiple sclerosis (Houndmills, Basingstoke, England)

Clinical and experimental immunology

Annals of neurology

Barts Health NHS Trust

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Barts Health NHS Trust

United Kingdom

Consultant Neurologist (Hon) :: Clinical Board Medicine (Neuroscience)

Queen Mary University of London

United Kingdom

Professor of Neurology :: The Blizard Institute, Centre for Neuroscience, Surgery and Trauma

Publications

Klaus Schmierer, Hans Lassmann
The shoulders we keep standing on: remembering Otto Marburg, a big brain in neurology and multiple sclerosis, at 150. Acta neuropathologica 147 (1) (2024)
Klaus Schmierer, Hans Lassmann
The shoulders we keep standing on: remembering Otto Marburg, a big brain in neurology and multiple sclerosis, at 150. Acta neuropathologica 147 (1) (2024)
Manuel Salavisa, Bader Mohamed, Kimberley Allen-Philbey, Andrea M Stennett, Thomas Campion, Klaus Schmierer
Parakinesia Brachialis Oscitans in a Patient With a First Manifestation of Multiple Sclerosis. Neurology. Clinical practice 13 (6) (2023)
Kimberley Allen-Philbey, Stefania De Trane, Amy MacDougall, Ashok Adams, Lucia Bianchi, Thomas Campion, Gavin Giovannoni, Sharmilee Gnanapavan, David W Holden, Monica Marta, Joela Mathews, Benjamin P Turner, David Baker, Klaus Schmierer
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis. Therapeutic advances in neurological disorders 16 (2023)
Klaus Schmierer
Honing in on magnetic resonance imaging predictors of multiple sclerosis pathology. Brain pathology (Zurich, Switzerland) (2023)
Safiya A Zaloum, Callum H Wood, Pooja Tank, Matthew Upcott, Nicola Vickaryous, Valerie Anderson, David Baker, Randy Chance, Nikos Evangelou, Katila George, Gavin Giovannoni, Katharine Elizabeth Harding, Aimee M Hibbert, Gillian Ingram, Stephen Jolles, Angray S Kang, Samantha Loveless, Stuart J Moat, Aidan Richards, Neil P Robertson, Francesca Rios, Klaus Schmierer, Mark Willis, Chu-Yueh Guo, Emma Clare Tallantyre
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple sclerosis (Houndmills, Basingstoke, England) 29 (8) (2023)
Anthony Seaton, David Baker, Anna Karin Hedström, L Alfredsson, Klaus Schmierer
Organic solvents and Multiple Sclerosis: the doubled risk dilemma. Occupational medicine (Oxford, England) 73 (6) (2023)
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 28 (13) (2022)
Gogem Topcu, Laura J Smith, Jacqueline R Mhizha-Murira, Nia Goulden, Zoë Hoare, Avril E R Drummond, Deborah Fitzsimmons, Nikos Evangelou, Klaus Schmierer, Emma Clare Tallantyre, Paul A Leighton, Kimberley Allen-Philbey, Andrea M Stennett, Paul Bradley, Clare Bale, James Turton, Roshan das Nair, null null
Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): protocol for a mixed-methods, multicentre feasibility randomised controlled trial. Pilot and feasibility studies 8 (1) (2022)
Nicola De Stefano, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Klaus Schmierer, Finn Sellebjerg, Patrick Vermersch, Heinz Wiendl, Birgit Keller, Sanjeev Roy, null null
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS. Neurology(R) neuroimmunology & neuroinflammation 9 (4) (2022)
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management (2022)
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management 13 (1) (2022)
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management (2022)
David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? Clinical and experimental immunology 207 (3) (2022)
David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? Clinical and experimental immunology 207 (3) (2022)
Amy R McDowell, Natalia Petrova, Daniele Carassiti, Marc E Miquel, David L Thomas, Gareth J Barker, Klaus Schmierer, Tobias C Wood
High-resolution quantitative MRI of multiple sclerosis spinal cord lesions. Magnetic resonance in medicine 87 (6) (2022)
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management 13 (1) (2022)
Klaus Schmierer, Heinz Wiendl, Celia Oreja-Guevara, Diego Centonze, Anita Chudecka, Sanjeev Roy, Ursula Boschert
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management 13 (1) (2022)
David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? Clinical and experimental immunology 207 (3) (2022)
Marija Cauchi, Mark Willis, Angela Andrews, Matthijs Backx, Wallace Brownlee, Helen L Ford, Bruno Gran, Stephen Jolles, Sian Price, Waqar Rashid, Klaus Schmierer, Emma Clare Tallantyre
Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical neurology (2022)
David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals? Clinical and experimental immunology (2021)
Klaus Schmierer, G Giovannoni
MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Commentary. Multiple sclerosis (Houndmills, Basingstoke, England) 27 (7) (2021)
Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao, Cesar Álvarez-González, Joela Mathews, Amy MacDougall, Andrea Stennett, Xia Zhou, Ozlem Yildiz, Ashok Adams, Lucia Bianchi, Camilla Blain, Christine Chapman, Karen Chung, Cris S Constantinescu, Catherine Dalton, Rachel A Farrell, Leonora Fisniku, Helen Ford, Bruno Gran, Jeremy Hobart, Zhaleh Khaleeli, Miriam Mattoscio, Sue Pavitt, Owen Pearson, Luca Peruzzotti-Jametti, Antonio Scalfari, Basil Sharrack, Eli Silber, Emma C Tallantyre, Stewart Webb, Benjamin P Turner, Monica Marta, Sharmilee Gnanapavan, Gunnar Juliusson, Gavin Giovannoni, David Baker, Klaus Schmierer
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Therapeutic advances in neurological disorders 14 (2021)
Emma Clare Tallantyre, Nicola Vickaryous, Valerie Anderson, Aliye Nazli Asardag, David Baker, Jonathan Bestwick, Kath Bramhall, Randy Chance, Nikos Evangelou, Katila George, Gavin Giovannoni, Andrew Godkin, Leanne Grant, Katharine E Harding, Aimee Hibbert, Gillian Ingram, Meleri Jones, Angray S Kang, Samantha Loveless, Stuart J Moat, Neil P Robertson, Klaus Schmierer, Martin J Scurr, Sita Navin Shah, Jessica Simmons, Matthew Upcott, Mark Willis, Stephen Jolles, Chu-Yueh Guo
COVID-19 Vaccine Response in People with Multiple Sclerosis. Annals of neurology (2021)
Edward J D Webb, David Meads, Ieva Eskytė, Helen L Ford, Hilary Louise Bekker, Jeremy Chataway, George Pepper, Joachim Marti, Yasmina Okan, Sue H Pavitt, Klaus Schmierer, Ana Manzano
The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. The patient 13 (5) (2021)
Saúl Reyes, Ide Smets, David Holden, Karina Carrillo-Loza, Tatiana Christmas, Lucia Bianchi, Francesca Ammoscato, Benjamin Turner, Monica Marta, Klaus Schmierer, Gavin Giovannoni, Sharmilee Gnanapavan
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. Neurology(R) neuroimmunology & neuroinflammation 7 (6) (2020)
Saúl Reyes, Mary Ramsay, Shamez Ladhani, Gayatri Amirthalingam, Neena Singh, Carlos Cores, Joela Mathews, Jonathan Lambourne, Monica Marta, Benjamin Turner, Sharmilee Gnanapavan, Chu-Yueh Guo, Klaus Schmierer, Gavin Giovannoni
Protecting people with multiple sclerosis through vaccination. Practical neurology 20 (6) (2020)
Sandra Amor, David Baker, Samia Joseph Khoury, Klaus Schmierer, Gavin Giovanonni
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad. Annals of neurology 87 (6) (2020)
Gauri Saxena, James M Moore, Meleri Jones, Gareth Pryce, Liaqat Ali, Georgia R Leisegang, Vivek Vijay, Samantha Loveless, Neil P Robertson, Klaus Schmierer, Gavin Giovannoni, Sharmilee Gnananpavan, David Baker, Emma C Tallantyre, Angray S Kang
Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology(R) neuroimmunology & neuroinflammation 7 (4) (2020)
Klaus Schmierer, David Baker
B cells and multiple sclerosis spinal cord pathology. Brain pathology (Zurich, Switzerland) 30 (4) (2020)
Natalia Petrova, Erik Nutma, Daniele Carassiti, James Rs Newman, Sandra Amor, Daniel R Altmann, David Baker, Klaus Schmierer
Synaptic Loss in Multiple Sclerosis Spinal Cord. Annals of neurology 88 (3) (2020)
G Giovannoni, P A Brex, D Dhiraj, J Fullarton, M Freddi, Barry S Rodgers-Gray, Klaus Schmierer
Glatiramer acetate as a clinically and cost-effective treatment of relapsing multiple sclerosis over 10 years of use within the National Health Service: Final results from the UK Risk Sharing Scheme. Multiple sclerosis journal - experimental, translational and clinical 5 (4) (2019)
Klaus Schmierer, Marc E Miquel
Magnetic resonance imaging correlates of neuro-axonal pathology in the MS spinal cord. Brain pathology (Zurich, Switzerland) 28 (5) (2019)
David Baker, G Pryce, L K James, Klaus Schmierer, G Giovannoni
Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis. European journal of neurology 27 (2) (2019)
Klaus Schmierer, Thomas Campion, Audrey Sinclair, Wim van Hecke, Paul M Matthews, Mike P Wattjes
Towards a standard MRI protocol for multiple sclerosis across the UK. The British journal of radiology 92 (1101) (2019)
Luigi Lavorgna, Francesco Brigo, Marcello Moccia, Letizia Leocani, Roberta Lanzillo, Marinella Clerico, Gianmarco Abbadessa, Klaus Schmierer, Claudio Solaro, Luca Prosperini, Gioacchino Tedeschi, Gavin Giovannoni, Simona Bonavita
e-Health and multiple sclerosis: An update. Multiple sclerosis (Houndmills, Basingstoke, England) 24 (13) (2018)
Nicolas Dubuisson, Monica Marta, Sharmilee Gnanapavan, Benjamin Turner, David Baker, Alison Thomson, Klaus Schmierer, Gavin Giovannoni
Inclusion criteria used in trials of people with progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 26 (3) (2018)
Zhifeng Mao, Cesar Alvarez-Gonzalez, Stefania De Trane, Ozlem Yildiz, Christo Albor, Gabriel Doctor, Derek Soon, George Pepper, Benjamin P Turner, Monica Marta, Joela Mathews, Gavin Giovannoni, David Baker, Klaus Schmierer
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? Multiple sclerosis journal - experimental, translational and clinical 4 (2) (2018)

Klaus Schmierer.css-eqlu8i{font-size:small;padding-left:4px;} (K Schmierer)

Publication Activity (10 Years)

Top Topics

Top Venues

Klaus Schmierer (K Schmierer)